Functionalized Nanoparticles, Methods and In Vivo Diagnostic System

Patent metadata

Field	Value
Publication number	US-2016287152-A1
Application number	US-201615083830-A
Country	US
Kind code	A1
Filing date	Mar 29, 2016
Priority date	Mar 30, 2015
Publication date	Oct 6, 2016
Grant date	—

Abstract

A nanoparticle conjugate includes a nanoparticle, first oligonucleotides of one or more types bound to the nanoparticle, each type of first oligonucleotide having a sequence, and targeting conjugates of one or more types, each type of targeting conjugate comprising a targeting entity and a second oligonucleotide bound to the targeting entity and having a sequence that is complementary to a sequence of a predetermined type of the first oligonucleotides, wherein the second oligonucleotide are covalently bound to a surface of the nanoparticle, a functional group on the surface of the nanoparticle, or one of the first oligonucleotide. Also provided are methods for making such nanoparticle conjugates and methods and devices for using such nanoparticle conjugates.

First claim

1 . A composition comprising:
a nanoparticle; first oligonucleotides of one or more types that are bound to the nanoparticle, each type of first oligonucleotide having a sequence; and targeting conjugates of one or more types, each type of targeting conjugate comprising a targeting entity and a second oligonucleotide bound to the targeting entity and having a sequence that is complementary to a sequence of a predetermined type of the first oligonucleotides, wherein the second oligonucleotide is covalently bound to a surface of the nanoparticle, a functional group on the surface of the nanoparticle, or one of the first oligonucleotides.

2 . The composition of claim 1 , wherein the composition includes two or more types of targeting conjugates and two or more types of first oligonucleotides.

3 . The composition of claim 1 , wherein the composition includes a single type of first oligonucleotide and two or more types of targeting conjugates.

4 . The composition of claim 1 , wherein the targeting entity comprises a member of a specific binding pair.

5 . A library comprising nanoparticle conjugates of one or more types, each type of nanoparticle conjugate comprising:
a nanoparticle; first oligonucleotides of one or more types that are bound to the nanoparticle, each type of first oligonucleotide having a sequence; and targeting conjugates of one or more types, each type of targeting conjugate comprising a targeting entity and a second oligonucleotide bound to the targeting entity and having a sequence that is complementary to a sequence of a predetermined type of the first oligonucleotides, wherein the second oligonucleotide is covalently bound to a surface of the nanoparticle, a functional group on the surface of the nanoparticle, or one of the first oligonucleotides.

6 . A method comprising providing a first nanoparticle conjugate comprising a nanoparticle and first oligonucleotides of one or more types bound to the nanoparticle, each type of first oligonucleotide having a sequence;
(a) contacting the first nanoparticle conjugate with targeting conjugates of one or more types, each type of targeting conjugate comprising a targeting entity and a second oligonucleotide bound to the targeting entity, wherein the contacting occurs under suitable hybridization conditions to form a second nanoparticle conjugate, wherein the second oligonucleotide has a sequence that is complementary to a sequence of the first oligonucleotides and wherein the second oligonucleotide includes a reactive group that binds to a surface of the nanoparticle, a functional group on the nanoparticle, or one of the first oligonucleotides; (b) washing the second nanoparticle conjugate; and (c) covalently reacting the reactive group of the second oligonucleotide of the second nanoparticle conjugate to the surface of the nanoparticle, a functional group on the nanoparticle, or one of the first oligonucleotides under suitable reaction conditions to form a third nanoparticle conjugate.

7 . The composition of claim 6 , wherein the second oligonucleotides are covalently bound to the surface or a functional group on the surface of the third nanoparticle conjugate.

8 . A method comprising:
(a) providing a first nanoparticle conjugate comprising a nanoparticle and a first oligonucleotide bound to the nanoparticle; (b) contacting the first nanoparticle conjugate with second oligonucleotides of one or more types, each type of second oligonucleotide comprising a targeting sequence and a sequence that is complementary to a sequence of the first oligonucleotide to produce a second nanoparticle conjugate, wherein said contacting occurs under suitable hybridization conditions; (c) extending the first oligonucleotide under suitable polymerase chain reaction conditions to produce an extended first oligonucleotide comprising a complementary targeting sequence that is complementary to the targeting sequence of the second oligonucleotide; (d) removing the second oligonucleotide from the second nanoparticle under suitable dehybridization conditions to produce a third nanoparticle conjugate; (e) washing the third nanoparticle conjugate; (f) contacting the third nanoparticle conjugate with a targeting conjugate of one or more types, each type of targeting conjugate comprising a targeting entity and a third oligonucleotide that is bound to the targeting entity, wherein the third oligonucleotide has a predetermined sequence that is complementary to the complementary targeting sequence of the extended first oligonucleotide, wherein the third oligonucleotide has a reactive group that is capable of covalently binding to a surface of the nanoparticle, a functional group on the nanoparticle, or the first oligonucleotide and wherein said contacting occurs under hybridization conditions to form a fourth nanoparticle conjugate.

9 . The method of claim 8 , further comprising;
(f1) covalently binding the third oligonucleotide to the surface of the nanoparticle, to a functional group on the nanoparticle, or to the first oligonucleotide to form a nanoparticle conjugate probe.

10 . The method of claim 8 , further comprising;
(g) extending the third oligonucleotide under suitable polymerase chain reaction conditions to produce a modified third oligonucleotide comprising a sequence that is complementary to the sequence of the first oligonucleotide; and (h) covalently reacting the reactive group of the modified third oligonucleotide with the surface of the nanoparticle or a functional group on the nanoparticle to form a nanoparticle conjugate probe.

11 . The method of claim 8 , wherein the method involves a single type of second oligonucleotide and a single type of targeting conjugate.

12 . The method of claim 8 , wherein the method involves two or more types of second oligonucleotide and two or more types of targeting conjugates.

13 . A method comprising:
(a) providing a first nanoparticle conjugate comprising a nanoparticle and a first oligonucleotide bound to the nanoparticle; (b) contacting the first nanoparticle conjugate with a second oligonucleotide of two or more types, each type of second oligonucleotide comprising a targeting sequence and a sequence that is complementary to a sequence of the first oligonucleotide to produce a second nanoparticle conjugate, wherein said contacting occurs under suitable hybridization conditions; (c) washing the second nanoparticle conjugate; (d) contacting the second nanoparticle conjugate with targeting conjugates of one or more types, each type of targeting conjugate comprising a targeting entity and a third oligonucleotide that is bound to the targeting entity, the third oligonucleotide having a predetermined sequence that is complementary to the targeting sequence of the second oligonucleotide, wherein said contacting occurs under suitable hybridization conditions to form a third nanoparticle conjugate; and (e) ligating the third oligonucleotide to the first oligonucleotide under suitable ligation conditions to form a fourth nanoparticle conjugate.

14 . The method of claim 13 , further comprising removing the second oligonucleotide of the fourth nanoparticle conjugate under suitable dehybridization conditions to form a nanoparticle conjugate probe.

15 . The method of claim 13 , further comprising covalently binding the second oligonucleotide of the fourth nanoparticle conjugate to form a nanoparticle conjugate probe.

16 . The method of claim 13 , wherein the method involves a single type of second oligonucleotide and a single type of targeting conjugate.

17 . The method of

Assignees

• Verily Life Sciences Llc

Inventors

• Schwartz Jerrod Joseph
• PALANIAPPAN Krishnan Kanna
• Vitari Alberto Clemente

Classifications

• A61K49/225

  Microparticles, microcapsules (gas-filled to be classified in A61K49/223) · CPC title

• A61B5/14546 Primary

  for measuring analytes not otherwise provided for, e.g. ions, cytochromes · CPC title

• A61K49/0093

  Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle · CPC title

• A61K49/222

  characterised by a special physical form, e.g. emulsions, liposomes · CPC title

• A61K49/0054

  Macromolecular compounds, i.e. oligomers, polymers, dendrimers · CPC title